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Introduction: The innate immune response molecules and their use as a predictor of mortality in cancer patients
with severe sepsis and septic shock are poorly investigated.
Objective: To analyze the value of interleukin (IL)-1ß, IL-6, IL-8, IL-10, IL-12, tumor necrosis factorα (TNF-α), sol-
uble triggering receptor expressed on myeloid cells 1 (sTREM-1), and high-mobility group box 1 (HMGB-1) as
predictors ofmortality in cancer patientswith severe sepsis and septic shock comparedwith septic patientswith-
out malignancies.
Design: Prospective, observational cohort study.
Setting: Tertiary level adult intensive care unit (ICU).
Subjects: Seventy-ﬁve patients with severe sepsis or septic shock, 40 with cancer and 35 without.
Interventions and Measurements: Laboratory data were collected at ICU admission, 24and 48 hours after. Plasma
concentrations of HMGB-1 and sTREM-1 were measured by enzyme-linked immunosorbent assay, whereas cy-
tokines were measured by cytometric bead array.
Results: Intensive care unit mortality in cancer and noncancer patients was 40% and 28.6% (P= .29), and 28-day
mortalitywas 45% and 34.3% (P= .34). Proinﬂammatory cytokines IL-1ß, IL-6, IL-8, IL-12, and TNF-α showed sig-
niﬁcantly higher values in the cancer group. Interleukin-10 at 48 hours (P= .01), sTREM-1 in all measurements
(P b .01) and HMGB-1 at 24 hours (P b .01) showed signiﬁcantly lower values in the cancer group. In addition, for
the cancer group, sTREM-1 at 24 hours (P= .02) and 48 hours (P= .01) showed higher levels in nonsurvivors
patients. The area under the receiver operating characteristic curve for predicting ICU mortality for sTREM-1
was 0.73 (95% conﬁdence interval, 0.57-0.89; P = .01). Multivariate logistic analysis showed that the days
spent in mechanical ventilation and levels of sTREM-1 and IL-1ß at 48 hours were independent predictors of
ICUmortality; corticosteroids requirement and levels of sTREM-1 and TNF-α at 24 hours were independent pre-
dictors of 28-day mortality.
Conclusions: Patients with cancer have different immune proﬁle in sepsis when comparedwith patients without
cancer, as demonstrated for levels of cytokines, sTREM-1 and HMGB-1. sTREM-1 and days spent in mechanical
ventilation proved to be good predictors of ICU and 28-day mortality in cancer patients.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
Sepsis represents one of the main reasons for hospitalization in in-
tensive care unit (ICU) causing high rates of mortality [1–3]. Notably,
cancer and sepsis have a strong association due to several reasons. For
instance, cancer treatments such as chemotherapy, radiation, and
major surgery alter the body defense barriers against microorganisms.
Cancer also affects the elderly, who present higher rates of infection.ealth Sciences: Infectology and
hool of Medicine, UFMG, Belo
ti).Moreover, sepsis may result from other effects related to the tumor
itself [4–6].
The inﬂammatory response triggered by microorganisms is charac-
terized by the release of proinﬂammatory (eg, interleukin [IL]-1ß, IL-6,
and tumor necrosis factor α [TNF-α]) and anti-inﬂammatory (eg, IL-
10) mediators that may determine clinical outcome [7–9]. Considering
the pathophysiology of sepsis, molecules related to immune processes
are potential biomarkers for diagnosis and prognosis of sepsis. There is
a high need to identify sepsis-related biomarkers that may help
physicians at the bedside to make clinical decisions.
One of such molecules is the high-mobility group box 1 (HMGB-1),
which is a protein found in the nucleus and cytoplasm with proinﬂam-
matory effects, such as the stimulation of the innate immune cells
Table 1
Characteristics of patientswith andwithout cancer admitted at ICU-HMDwith severe sep-
sis or septic shock
Variable All (n = 75) Cancer (n = 40) Controls (n = 35) P
Age (y), mean (SD) 67 (17.9) 65.5 (17.5) 68.7 (18.3) .44a
Male (%) 56 55 57.1 .85b
Type of cancer (%)
Solid tumors 31 (77.5)
Hematologic
tumors
9 (22.5)
Procedure (%)
Ward 41.3 47.5 34.3 .24b
ED 40 30 51.4 .05b
OR 14.7 22.5 5.7 .04b
Others 4.0 0 8.6
Comorbidities (%)
SAH 58.7 50 68.6 .10b
DM 25.3 25 25.7 .94b
COPD 17.3 17.5 17.1 .96b
CAD 16 15 17.1 .80b
CHF 14.7 15 14.3 .93b
Hypothyroidism 10.7 0 22.9 .001c
ED indicates emergency department; OR, operating room; SAH, systemic arterial hyper-
tension; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease; CAD, coro-
nary artery disease; CHF, congestive heart failure; HMD, Mater Dei Hospital.
a Student t test.
b χ2 Test.
c Fisher test.
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An elevated HMGB-1 plasma concentration has been shown in patients
with severe sepsis and septic shock, being correlated with the severity
of the disease [10] and associated with mortality in humans with septic
shock admitted at the ICU [11].
The soluble triggering receptor expressed on myeloid cells 1
(sTREM-1) is a member of the immunoglobulin superfamily expressed
in neutrophils, macrophages, and monocytes that increases after bacte-
ria and fungi stimuli. sTREM-1 plasma levels were associated with the
diagnosis of sepsis [12,13]. Some authors demonstrated a good correla-
tion of sTREM-1 with the severity and prognosis of sepsis [14], but
others failed to demonstrate it [15,16]. One single-center study reported
that sTREM-1 levels on admission were an independent predictor of
survival in patients with severe sepsis [38].
In cancer patients, the role of these biomarkers still needs further in-
vestigation. Traditional predictors of mortality such as neutropenia,
seen as a negative prognostic determinant, failed to show a signiﬁcant
association with outcome in several studies with cancer patients
[18–21]. In febrile neutropenic infected patients, one study showed an
association between sTREM-1 and mortality [17].
This study aims to determine clinical and molecular predictors of
mortality in cancer patients admitted at ICUwith severe sepsis and sep-
tic shock, compared with individuals without cancer.
2. Material and methods
2.1. Study settings and subjects
Patients were enrolled at the ICU of the Mater Dei Hospital, Belo
Horizonte, Minas Gerais, Brazil, from May 2012 to April 2014. This pri-
vate hospital has 330 beds, with a 50-bed mixed medical-surgical ICU,
receiving an average of 1600 admissions per year.
Adult patientswith cancer admitted in ICUwith severe sepsis or sep-
tic shock were included in the study. Inclusion criteria were as follows:
patients 18 years and older with cancer of any site in activity or in re-
mission for less than 5 years. Criteria for severe sepsis or septic shock
were followed according to the Sepsis Consensus Conference [22]: pa-
tients who stayed in the ICU for less than 24 hours, treatment with an-
tibiotics for more than 48 hours before ICU admission, palliative care, or
suspension of antibiotics. The control group comprised matched pa-
tients with severe sepsis or septic shock without cancer.
All patients included agreed to participate in the study after reading
and signing thewritten informed consent. The Research Ethics Commit-
tees of the Federal University of Minas Gerais and of the Mater Dei
Hospital, Belo Horizonte, approved this study.
2.2. Data collection
Sepsis-related Organ Failure Assessment (SOFA) [39] and Acute
Physiology and Chronic Health Evaluation II (APACHE II) [40] scores
were measured within the ﬁrst 24 hours of inclusion from laboratory
data and nursing records.
Blood sampleswere collected at ICU admission (D0), 24 (D1), and 48
(D2) hours after via venipuncture or intra-arterial catheter when indi-
cated. After centrifugation, the plasmawas stored at−80°C for analysis
at the Interdisciplinary Laboratory ofMedical Investigation at the School
of Medicine, UFMG. Plasma concentrations of HMGB-1 and sTREM-1
were measured with speciﬁc enzyme-linked immunosorbent assay
kits (IBL International HMGB1 ELISA, Hamburg, Germany, and R&D
SYSTEMS Human TREM-1 DuoSet, Minessota, Min), whereas IL-1ß,
IL-6, IL-8, IL-10, TNF-α, and IL-12p70 were assayed by the Cytometric
Bead Array Human Inﬂammation kit (BD Biosciences, San Diego, Calif)
according to the manufacturer's protocol.
Lower detection limits were reported as 7.2 pg/mL for IL-1ß,
2.5 pg/mL for IL-6, 3.6 pg/mL for IL-8, 3.3 pg/mL for IL-10, 3.7 pg/mLfor TNF-α, 1.9 pg/mL for IL-12p70, 0.1 ng/mL for HMGB-1, and
3.88 pg/mL for sTREM-1.
2.3. Statistical analysis
Categorical variables were described according to their absolute and
relative frequencies. Continuous variableswere expressed asmeans and
SD, or median and interquartile range according to their distribution.
The normality test used was Kolmogorov-Smirnov.
Comparison between groups was performed using Student t test or
Mann-Whitney U test for continuous variables according to their distri-
bution. Qualitative variables were compared using the χ2 or Fisher exact
test, as appropriate.
Characteristics of survivors vs nonsurvivors were compared using
univariate analysis and receiver operating characteristics (ROC) curves
to evaluate the prognostic value of biomarkers in predicting mortality.
Spearman test was used to assess correlations among variables.
Amultivariate binary logistic regression analysis was also performed
to determine which factors were associated with ICU and 28-day mor-
tality. Variables with a P value less than .25 after univariate analysis
were included in the multivariate analysis. The Hosmer-Lemeshow
test was used to check the ﬁt of this model. A 2-sided P b .05 was used
to determine statistical signiﬁcance.
Statistical Package Social Science (SPSS, Chicago, Ill) 19.0 program
was used for calculations.
3. Results
In the period betweenMay 2012 and April 2014, 2991 patients were
admitted in the ICU. Forty-seven cancer patients with severe sepsis or
septic shock were analyzed for inclusion. Seven patients were excluded
for not signing the consent form (n= 2), for using antibiotics for more
than 48 hours before admission (n = 2), or for the deﬁnition of pallia-
tive care (n = 3). Consequently, 40 patients were enrolled in the
study. The control group comprised 35 noncancer patients with severe
sepsis or septic shock, matched by age and sex.
Demographic and clinical data are presented in Tables 1 and 2,
respectively. The main sources of ICU admissions were the hospital
Table 2
Clinical characteristics of ICU stay of patients with and without cancer admitted at ICU-HMD with severe sepsis or septic shock
Variable All (n = 75) Cancer (n = 40) Controls (n = 35) P
Norepinephrine use (%) 80 77.5 82.9 .56a
Dobutamine use (%)b 50.7 57.5 42.9 .20a
Vasopressine use (%)b 9.3 7.5 11.4 .69c
Corticosteroids use (%)d 37.3 40 34.3 .82a
Site of infection (%)
Lung 45.3 32.5 60 .01
Abdomen 20 27.5 11.4 .08
Bloodstream 14.7 15 14.3 .93
Urinary 9.3 12.5 5.7 .31
Skin 4 5 5.7 .37
Microorganism (%)
Gram negative n = 36 n = 21 n = 15 .39a
Gram positive 58.3 52.4 66.6 .84a
Polimicrobian 25 23.8 26.7 .62c
Yeast 11.1 14.3 6.7 .50c
Without identiﬁcation 5.5 9.5 0 .40a
Laboratory data 52 52.5 57.2
GL D0 (×1000/mL), median (IQR) 12.5 (7.6-17.8) 9.4 (4.3-16.6) 14.5 (9.9-18.9) b .01e
GL D1 (×1000/mL), median (IQR) 10.6 (7.5-15) 9.4 (5.6-12.5) 12.3 (9.4-16.3) b .01e
GL D2 (×1000/mL, median (IQR) 10.2 (7.3-13.8) 9.3 (5.7-13.7) 11.2 (9-13.8) .05e
Neut. D0 (×1000/mL), median (IQR) 10.2 (4.8-14.7) 7.1 (2.6-12.1) 12.4 (7.8-15.8) b .01e
Neut. D1 (×1000/mL), median (IQR) 8.4 (5.2-11.9) 6.4 (2-9.6) 9.7 (7.8-14.3) b .01e
Neut. D2 (×1000/mL), median (IQR) 8.1 (5.2-10.7) 6.2 (3.2-10.1) 8.9 (7.4-12.5) b .01e
Hemodialysis (%) 28 22.5 34.3 .25a
MV days, median (IQR) 4 (1-14) 3.5 (0.2-12) 6 (2-18) .09e
Length of ICU stay, median (IQR) 11 (4-20) 10 (3-14) 12 (7-23) .04e
Length of hospital stay, median (IQR) 23 (11-48) 20 (10-39) 28 (15-50) .14e
APACHE II, mean (SD) 19.3 (5.4) 19.9 (5.1) 18.7 (5.8) .33f
SOFA D0, mean (SD) 6.8 (2.8) 6.2 (2.7) 7.4 (2.9) .06f
ICU mortality (%) 34.7 40 (n = 16) 28.6 (n = 10) .29a
Mortality 28 d (%) 40 45 (n = 18) 34.3 (n = 12) .34a
MV indicates mechanical ventilation; IQR: interquartile range; HMD, Mater Dei Hospital.
a χ2 Test.
b Requirement in the ﬁrst 72 hours of inclusion.
c Fisher test.
d Requirement of corticosteroids (hydrocortisone for the suspected adrenal insufﬁciency).
e Mann-Whitney U test.
f Student t test.
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control group.
The global mortality rate in ICU and 28-day was 34.7% and 40%, re-
spectively. Intensive care unit and 28-day mortality rates in cancer pa-
tients were, respectively, 40% and 45%, whereas in the noncancer
group, they were 28.6% and 34.3% (Table 2).
Regarding tumor type, 77.5% were solid tumors and 22.5% were he-
matologic malignancies. Metastases were observed in 40% of cases. Ele-
vatedmortality in ICUwas noticed in patients with hematologic tumors
(55.5%, P= .27) and with metastases (56.3%, P= .08).
Total leukocytes count in D0 and D1, and neutrophils at all times
were lower in cancer patients. Neutropeniawas found only in 5 patients
(12.5%), all of whom with cancer (Table 2).
Serum levels of the 6 measured cytokines, IL-1ß, IL-6, IL-8, IL-10,
TNF-α, IL-12p70, and sTREM-1 at the 3 “”time points, and HMGB-1 at
24 hours for patients with and without cancer are shown in Table 3
and Fig. 1. Serum levels of IL-1ß, IL-6, IL-8, TNF-α, and IL-12 showed sig-
niﬁcantly higher values in the cancer group, mainly at D0 and D1. In
contrast, IL-10 at D2, sTREM-1 at all time points, and HMGB-1 at D1
showed signiﬁcantly lower values in cancer patients.
Cancer patients who died in the ICU showed higher levels of sTREM-
1 at 24 and 48 hours, and lower levels of TNF-α at 24 hours (Table 4). No
difference in levels of sTREM-1 between patients with solid tumors or
hematologic diseases was found (sTREM D0: 780 pg/mL vs 665 pg/mL,
P = .8; sTREM D1: 665 pg/mL vs 677 pg/mL, P = .52; sTREM D2: 780
pg/mL vs 659 pg/mL, P= .98).
Regarding the severity of sepsis, 80% of patients in cancer group had
septic shock. We found higher levels of sTREM-1 in patients with septic
shock at the 3 measured time points than those in patients with severesepsis, with statistically signiﬁcance difference (sTREM D0: 873 pg/mL
vs 256 pg/mL, P= .003; sTREM D1: 750 pg/mL vs 183 pg/mL, P= .01;
sTREM D2: 780 pg/mL vs 403 pg/mL, P= .009).
The area under the ROC curve for sTREM-1 in D1 and D2 to deter-
mine ICU and 28-day mortality in cancer patients is shown in Fig. 2.
After multivariate analysis to determine predictors of mortality in
ICU in cancer patients, the days spent in invasivemechanical ventilation
and higher levels of sTREM-1 at 48 hours appeared to be predictors of
mortality. Likewise, elevated levels of IL-1ß after 48 hours predicted re-
duced mortality (Table 5; Supplementary Table 7).
In patients with cancer, the predictors of 28-day mortality were use
of corticosteroids and higher levels of sTREM-1 at 24 hours. Reduced
levels of TNF-α at 24 hours showed to be protective (Table 6). Univari-
ate analyses are shown in Supplementary Table 8.
In noncancer patients, the predictor of ICU and 28-daymortalitywas
days spent in invasive mechanical ventilation, which increased the risk
of death in 14% and 24%, respectively. The increase in platelet count at
48 hours determined a reduction in mortality risk (Supplementary
Tables 9 and 10). None of the molecules tested were statistically signif-
icant to predict the outcome in noncancer patients.
4. Discussion
To our knowledge, this is the ﬁrst study in cancer patients that has
simultaneously assessed clinical and experimental data to determine
predictors of ICU and 28-day mortality. In this study, the only clinical
variables that showed to be predictive of mortality were the days
spent in invasive mechanical ventilation and steroids requirement em-
phasizing the need for others biomarkers at bedside. It is worth
Table 3
Median serum levels of cytokine and inﬂammatory mediators at ICU admission and 24 and 48 hours later in septic patients with and without cancer
Variable All Cancer Controls Pa
IL-8 D0 (pg/mL), median (IQR) 277.6 (109-1008) 487.5 (202-1325) 122.1 (71-399) .001
IL-8 D1 (pg/mL), median (IQR) 133.74 (49-322) 173.13 (98-472) 78.9 (27-150) .001
IL-8 D2 (pg/mL), median (IQR) 146.34 (61-340) 148.65 (65-354) 131.78 (37-346) .50
IL-1β D0 (pg/mL), median (IQR) 1.37 (1-4.71) 2.49 (1.13-5.0) 1.06 (0.99-3.13) b .01
IL-1β D1 (pg/mL), median (IQR) 1.06 (0.95-2.3) 1.20 (1.0-2.69) 0.99 (0.89-1.23) b .01
IL-1β D2 (pg/mL), median (IQR) 1.09 (1.0-3.3) 1.14 (1.01-3.11) 1.09 (0.99-4.22) .59
IL-6 D0 (pg/mL), median (IQR) 669.6 (143-3759) 929.47 (309-5512) 295.02 (83-1676) .01
IL-6 D1 (pg/mL), median (IQR) 235.67 (65-1192) 463.25 (129-1666) 113.13 (29-789) .01
IL-6 D2 (pg/mL), median (IQR) 242.80 (88-940) 242.8 (111-745) 233.81 (51-1169) .75
IL-10 D0 (pg/mL), median (IQR) 20.30 (4.4-110) 33.27 (4.8-111) 16.6 (3.5-125) .55
IL-10 D1 (pg/mL), median (IQR) 7.20 (3-18.2) 7.56 (4.3-16.6) 5.94 (2.2-24.2) .23
IL-10 D2 (pg/mL), median (IQR) 7.05 (3.45-22) 4.99 (3.1-9.85) 12.65 (4.3-31.5) .01
TNF D0 (pg/mL), median (IQR) 1.07 (0.94-1.8) 1.07 (0.99-1.68) 1.02 (0.93-1.91) .60
TNF D1 (pg/mL), median (IQR) 1.02 (0.93-1.28) 1.07 (0.99-1.53) 0.99 (0.89-1.08) .01
TNF D2 (pg/mL), median (IQR) 1.02 (0.99-1.72) 1.06 (0.99-1.62) 1.02 (0.93-2.7) .54
IL-12 D0 (pg/mL), median (IQR) 0.57 (0.55-1.35) 0.59 (0.57-1.95) 0.57 (0.50-0.98) .02
IL-12 D1 (pg/mL), median (IQR) 0.5 (0.51-1.71) 0.57 (0.55-1.82) 0.55 (0.51-1.10) .24
IL-12 D2 (pg/mL), median (IQR) 0.61 (0.56-1.97) 0.61 (0.57-1.90) 0.61 (0.55-2.08) .92
sTREM D0 (pg/mL), median (IQR) 925.95 (500-925) 702.05 (351-1048) 1701.9 (809-3607) b .01
sTREM D1 (pg/mL), median (IQR) 873.16 (520-2507) 677.93 (389-1029) 2212 (726-5725) b .01
sTREM D2 (pg/mL), median (IQR) 851.41 (541-1907) 708.09 (412-1055) 1725 (775-4092) b .01
HMGB1 D1 (ng/mL), median (IQR) 4.80 (2.54-7.50) 3.63 (1.23-5.75) 5.75 (3.94-8.78) b .01
IQR indicates interquartile range.
a Mann-Whitney U test.
Fig. 1. Levels of sTREM-1 at 0 h, 24 hours and 48 hours and HMGB1 at 24 hours in patients with and without cancer.
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Table 4
Median serum levels of cytokine and inﬂammatory mediators at inclusion and 24 and
48 hours in cancer patients who died in ICU with severe sepsis and septic shock
ICU mortality
Variable Yes No Pa
IL-8 D0 (pg/mL), median (IQR) 672.3 (217-1642) 487.5 (198-1010) .64
IL-8 D1 (pg/mL), median (IQR) 330.9 (125-627) 139.6 (88-406) .11
IL-8 D2 (pg/mL), median (IQR) 312.3 (102-409) 126.7 (65-165) .08
IL-1β D0 (pg/mL), median (IQR) 1.49 (1.12-3.84) 3.09 (1.13-7.11) .36
IL-1β D1 (pg/mL), median (IQR) 1.15 (1.03-2.27) 1.23 (1.0-2.69) .29
IL-1β D2 (pg/mL), median (IQR) 1.13 (1.04-1.49) 1,09 (0,99-2,99) .37
IL-6 D0 (pg/mL), median (IQR) 929.4 (460-7003) 886.0 (292-3719) .57
IL-6 D1 (pg/mL), median (IQR) 639.4 (208-4064) 336.3 (66-925) .11
IL-6 D2 (pg/mL), median (IQR) 483.45 (120-1275) 191.9 (113-336) .26
IL-10 D0 (pg/mL), median (IQR) 18.3 (3.7-88.4) 36.7 (4.9-138) .43
IL-10 D1 (pg/mL), median (IQR) 11.5 (2.4-31.3) 6.49 (4.7-13.4) .75
IL-10 D2 (pg/mL), median (IQR) 6.41 (2.7-13.6) 4.51 (3.0-8.0) .92
TNF D0 (pg/mL), median (IQR) 1.02 (0.93-1.18) 1.07 (1.0-2.99) .14
TNF D1 (pg/mL), median (IQR) 1.02 (0.94-1.18) 1.08 (0.99-1.57) .05
TNF D2 (pg/mL), median (IQR) 1.05 (0.93-1.48) 1.08 (0.99-1.57) .48
IL-12 D0 (pg/mL), median (IQR) 0.59 (0.56-0.98) 0.61 (0.57-2.09) .26
IL-12 D1 (pg/mL), median (IQR) 0.57 (0.55-1.82) 0.57 (0.51-1.90) .77
IL-12 D2 (pg/mL), median (IQR) 0.59 (0.57-0.98) 0.61 (0.55-1.98) .37
sTREM D0 (pg/mL), median (IQR) 848 (584-1312) 558 (245-1058) .10
sTREM D1 (pg/mL), median (IQR) 805 (585-1603) 552 (163-837) .02
sTREM D2 (pg/mL), median (IQR) 879 (720-1677) 531 (338-932) .01
HMGB1 D1 (ng/mL), median (IQR) 3.91 (2.47-7.64) 2.95 (0.36-5.24) .13
a Mann-Whitney U test.
Fig. 2.ROC curve for sTREM1 levels at D1 andD2 to determine ICU and 28-daymortality in
cancer patients admitted at ICU with severe sepsis or septic shock.
Table 5
Multivariate analysis to assess ICU predictors of mortality in cancer patients with severe
sepsis or septic shock
Variable Univariate Final model P
OR 95% CI OR 95% CI
Constant – – 0.124 – –
MV LOS 1.214 1.067-1.381 1.301 1.080-1.567 .006
IL1ß-D2 0.563 0.293-1.080 0.245 0.064-0.938 .040
sTREM-1 D2 1.001 0.999-1.001 1.002 1.000-1.004 .047
MV LOS indicates mechanical ventilation length of stay, OR, odds ratio; CI, conﬁdence interval.
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mortality in noncancer patients as well.
Themortality of patients with cancer admitted at ICU for severe sep-
sis and septic shock is high. In this study, the 28-daymortality was 45%.
This ﬁgure was similar to those observed by other authors. For instance,
Taccone et al [23] analyzed a subset of patients with cancer of the SOAP
study and observed mortality rates around 50% in sepsis. Pène et al [24]
reported 28-day mortality of 52.7% in cancer patients with septic shock
in Europe. In the United States, Williams et al [25] found lower rates
(37.8%), but patients in all stages of sepsis were considered.
Mortality in ICU was 40% in cancer group, a number similar to that
found by Ñamendys-Silva et al [26] in Mexico. In Brazil, Soares et al
[18] reported a 44% of mortality rate in a cancer group admitted at ICU
due to medical causes, not speciﬁcally to sepsis, which accounted only
for 15% of admissions. Other authors such as Staudinger et al [27],
Regazzoni et al [28], and Rosolem et al [29] reported an ICU mortality
rate of 62%, 53.4%, and 51 % in septic patients with cancer admitted at
the ICU, respectively.
The most common site of infection in our patients was the lung in
both groups, corresponding to previously published data [29,30]. Infec-
tions caused by gram-negative bacteria were the most frequent in both
groups (58%), as also observed by Pène et al [24] (86%) and Rosolem
et al [29] (53%).
Cancer patients came mainly from ward and noncancer patients
from emergency department, suggesting that oncologic patients were
ﬁrst admitted to the ward and then transferred to the ICU. This may re-
ﬂect the clinical debate onwhether cancer patientsmight or not beneﬁt
of ICU stay. In some cases, this could delay proper treatment. Although
we did not observe difference in mortality rates between the groups,
Larché et al [30] and Thiery et al [31] showed increased mortality in
cancer patientswhowere denied their admission in ICU for not present-
ing “sufﬁcient” severity, which resulted in later admissions and in-
creased mortality.
Although we did not observe difference in SOFA and APACHE II
scores between groups, patients with cancer died more even requiring
less time on invasive mechanical ventilation. Accordingly, SOFA and
APACHE II scores were not independent predictors of mortality in our
study. These ﬁndings might suggest that SOFA and APACHE II are lessaccurate in cancer patients, emphasizing the need of individualized as-
sessment of patient subgroups with severe sepsis and septic shock.
The number of days spent in mechanical ventilation was the only
clinical predictor of mortality in both groups (Table 5; Supplementary
Tables 9 and 10). These results coincide with other studies that evaluat-
ed the need formechanical ventilation support and its relationshipwith
mortality [24,27,32,33]. It is worth mentioning that increasing platelet
count in 1000/mL after 48 hours reduced the risk of death in patients
without cancer, corroborating the view that organ dysfunction is a
marker of prognosis (Supplementary Table 9).
Table 6
Multivariate analysis to assess 28-day predictors of mortality in cancer patients admitted
to the ICU with severe sepsis or septic shock
Variable Categories Univariate Final Model P
OR 95% CI OR 95% CI
Steroids No 1.000 – 1.000 – –
Yes 3.333 0.889-12.48 6.168 1.123-33.879 .036
TNF-α D1 – 0.181 0.020-1.575 0.111 0.018-0.699 .019
sTREM-1 D1 – 1.001 0.999-1.001 1.002 1.000-1.004 .030
OR indicates odds ratio; CI, conﬁdence interval.
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but did not inﬂuence the prognosis. The number of neutropenic patients
in this studywas only 5,with 1 death in ICU. Despite the limited number
of patients, these data coincide with those observed by Regazzoni et al
[34], Póvoa et al [35], and Souza-Dantas et al [21], which found no asso-
ciation between neutropenia and mortality in cancer patients.
The role of components of the immune response as a biomarker of
mortality in patients presenting neoplastic disease with severe sepsis
and septic shock still needs investigation. In this study, 6 serum cyto-
kines measured at 3 times points (ICU admission and 24 and 48 hours
later) showed that the inﬂammatory response was more pronounced
in patients with cancer. This was evidenced by an increase in the proin-
ﬂammatory cytokines IL-1ß, IL-6, IL-8, and TNF-α, and reduced levels of
IL-10. Interestingly, after multivariate analysis, we observed that lower
levels of IL-1ß and TNF-α showed to be protective in the cancer
group. It seems to indicate that cancer patients with a less intense in-
ﬂammatory response have a higher survival rate, emphasizing the po-
tential damage of dysregulated immune response.
sTREM-1 has proinﬂammatory effects, for example, it stimulates the
release of IL-8, TNF-α, and IL-1ßwhile inhibiting IL-10. In previous stud-
ies including noncancer patients, sTREM-1 showed a strong association
with sepsis diagnosis [12,13,16]. Although sTREM-1 was lower in the
cancer group, those patients who died had higher levels. These ﬁnding
is in accordance with some authors investigating noncancer patients
with sepsis [14,16,36,37], and in one retrospective study including pa-
tients with chemotherapy-associated febrile neutropenia, higher levels
of sTREM-1 demonstrated good correlationwith severity and the devel-
opment of complications [17]. The reduced levels of sTREM-1 found in
patients with cancermight be associatedwith the reduction in total leu-
kocyte and neutrophil counts.
It is noteworthy that none of the assayed molecules in this study
were good predictors of mortality in noncancer patients.
This study has several limitations thatmust be considered for results
interpretation. The sample size was limited and the study was conduct-
ed in a single centerwith the inclusion of patientswith different types of
cancer. Patients were followed up only during stay in hospital. In addi-
tion, we assessed only the need for invasive mechanical ventilation,
not evaluating the need for noninvasive mechanical ventilation. This
may explain the lower number of days in invasive mechanical ventila-
tion observed in cancer patients.
In conclusion, we found that sTREM-1 can predict ICU and 28-day
mortality in cancer patients with severe sepsis and septic shock. These
patients also have an intense proinﬂammatory response when com-
pared with noncancer patients, as demonstrated by increased levels of
IL-1ß, IL-6, IL-8, IL-12, and TNF-α.
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